MicroRNA modulation in complex regional pain syndrome

Orlova et al.
MicroRNA modulation in complex regional pain syndrome

Irina A Orlova1†, Guillermo M Alexander2†, Rehman A Qureshi3†, Ahmet Sacan3, Alessandro Graziano1, James E Barrett1, Robert J Schwartzman2 and Seena K Ajit1*

Abstract

Background: Aberrant expression of small noncoding RNAs called microRNAs (miRNAs) is a common feature of several human diseases. The objective of the study was to identify miRNA modulation in patients with complex regional pain syndrome (CRPS) a chronic pain condition resulting from dysfunction in the central and/or peripheral nervous systems. Due to a multitude of inciting pathologies, symptoms and treatment conditions, the CRPS patient population is very heterogeneous. Our goal was to identify differentially expressed miRNAs in blood and explore their utility in patient stratification.

Methods: We profiled miRNAs in whole blood from 41 patients with CRPS and 20 controls using TaqMan low density array cards. Since neurogenic inflammation is known to play a significant role in CRPS we measured inflammatory markers including chemokines, cytokines, and their soluble receptors in blood from the same individuals. Correlation analyses were performed for miRNAs, inflammatory markers and other parameters including disease symptoms, medication, and comorbid conditions.

Results: Three different groups emerged from miRNA profiling. One group was comprised of 60% of CRPS patients and contained no control subjects. miRNA profiles from the remaining patients were interspersed among control samples in the other two groups. We identified differential expression of 18 miRNAs in CRPS patients. Analysis of inflammatory markers showed that vascular endothelial growth factor (VEGF), interleukin1 receptor antagonist (IL1Ra) and monocyte chemotactic protein-1 (MCP1) were significantly elevated in CRPS patients. VEGF and IL1Ra showed significant correlation with the patients reported pain levels. Analysis of the patients who were clustered according to their miRNA profile revealed correlations that were not significant in the total patient population. Correlation analysis of miRNAs detected in blood with additional parameters identified miRNAs associated with comorbidities such as headache, thyroid disorder and use of narcotics and antiepileptic drugs.

Conclusions: miRNA profiles can be useful in patient stratification and have utility as potential biomarkers for pain. Differentially expressed miRNAs can provide molecular insights into gene regulation and could lead to new therapeutic intervention strategies for CRPS.

Keywords: MicroRNA, biomarker, pain, CRPS
Background

Complex regional pain syndrome (CRPS) is a disabling chronic neuropathic pain syndrome that can affect one or more extremities. The broad spectrum of symptoms includes pain, inflammation, sensory dysfunction, impaired motor function, and trophic disturbances [1-4]. CRPS is subdivided into CRPS-I (reflex sympathetic dystrophy) and CRPS-II (causalgia), based on the absence or presence of documented nerve injury respectively [5]. The complex multifactor pathogenesis of CRPS includes inflammatory, vascular, sympathetic nervous system, cortical, and spinal mechanisms. The pathophysiology of CRPS is not completely understood and the diagnosis is based solely on clinical observations. Not all disease mechanisms are equally prominent in each patient and no single therapeutic modality is sufficient to attenuate all of the symptoms.

Small nonprotein coding endogenous ~22 nucleotide RNA molecules called microRNAs (miRNAs) have attracted considerable attention in an effort to dissect the molecular changes in various disease models. miRNAs play important roles in the regulation of gene expression and function by binding to the 3’ untranslated region (3’-UTR) of target messenger RNAs (mRNAs) that, in turn, causes cleavage or repression of translation of these mRNAs. Each miRNA species regulates multiple genes, and most mRNAs targets contain multiple miRNA binding sites within their 3’-UTR, suggestive of a complex regulatory network [6]. As aberrant miRNA expression is a common feature in a variety of human diseases, these molecules offer novel avenues for the identification of biomarkers and new opportunities for the discovery and validation of novel therapeutic targets [7].

It was recently demonstrated that miRNAs are present in the serum and plasma of humans and other mammals, such as rats, mice, cows and horses [8,9]. This finding opens up the feasibility of using miRNAs as biomarkers of disease. Though the stability of miRNAs in serum was the initial concern, it has now been demonstrated that these circulating miRNAs are protected from plasma RNase activity and are, in fact quite stable [8]. The existence of tumor-related miRNAs in serum indicates the potential usefulness of miRNAs as clinical diagnostic biomarkers of various cancers [10]. In another recent report, dozens of stable miRNAs were detected in saliva and two miRNAs were present in significantly lower levels in the saliva of patients with oral squamous cell carcinoma compared to control subjects [11]. Further evidence for the presence of miRNAs in body fluids came from an analysis of urine samples [12]. Four miRNAs were significantly elevated in urine from urothelial bladder cancer patients, demonstrating the utility of miRNAs as a noninvasive diagnostic option [13]. All of these studies illustrate the potential use of miRNAs as novel biomarkers amenable to clinical diagnosis in translational medicine [12,14-16]. Biomarkers can be used to determine the propensity to develop a disease, measure its progress, or predict prognosis [17]. In clinical trials, biomarkers can help in patient stratification and thereby increase the chances of a successful outcome by targeting the appropriate population. In addition, biomarkers can pave the way to individualize treatment and thereby usher in a new era in personalized medicine [18].

A number of studies have addressed miRNA changes in rodent models of inflammatory and neuropathic pain indicating an essential role for miRNAs in altering pain threshold [19-25]. Although deregulation of miRNA is now a well-established phenomenon in a number of human diseases including osteoarthritis pain [26], there are, to our knowledge, no published reports investigating the role of miRNA expression in patients with neuropathic pain. The objective of this study was to investigate differential expression of miRNAs in blood from patients with CRPS as an initial step to determine its utility as a novel approach to biomarker development. Correlation studies also were performed using miRNA profiles, inflammatory markers and other disease parameters. Eighteen miRNAs were significantly different between patients and control subjects compared to three inflammatory and immune related markers. Clustering of 60% of patients with CRPS on the basis of the miRNA profile suggests that clinically relevant stratification of the patient population is possible on the basis of alterations in miRNA expression.

Methods

Standard protocol approvals, registrations, and patient consents

All subjects were enrolled after giving informed consent as approved by the Drexel University College of Medicine Institutional Review Board.

Inclusion and exclusion criteria

Patients with CRPS were recruited from the pain clinic of Drexel University College of Medicine and fulfilled the International Association for the Study of Pain (IASP) diagnostic criteria for CRPS [5]. Healthy control subjects were recruited from the general public. The exclusion criteria for all subjects included pregnancy, recent infection, lupus erythematosus, HIV/AIDS, rheumatoid arthritis, recent extracorporeal circulation (hemodialysis, bypass surgery, plasmapheresis), bone marrow transplant, immunosuppressive therapy, blood disorders (anemia, leukemia), thymectomy, or sarcoidosis.

Patient evaluation

All patients with CRPS received a complete neurological examination and pain evaluation (performed by RJS). Overall pain levels were determined on a 0-10 numerical rating scale (NRS) (0 = no pain, 10 = worst possible
fold change was calculated from raw CT values using the \( CT \) values. Samples with CT values of 32 and above were quantile normalized to the cycle threshold data analysis. The manufacturer’s protocol. RNA concentration was measured using Nanodrop 1000 (NanoDrop Technologies, Wilmington, DE).

Taqman Low Density Array (TLDA) microfluidic cards version A and B (Applied Biosystems, Foster City, CA) were used to profile miRNAs and the protocol recommended by the vendor was followed. We used 50 ng of total RNA in each reaction for cDNA synthesis using a TaqMan microRNA reverse transcription kit and human megaplex RT primers for Pool A and Pool B. Preamplification was done using TaqMan preamplification master mix and human megaplex preamplification primers corresponding to Pool A and Pool B. TLDA cards were assayed on an ABI PRISM 7900 Sequence detector using universal thermal cycling conditions of 50°C for 2 minutes, 95°C for 10 minutes, then 40 cycles of 95°C for 15 seconds and 60°C for 1 minute. The threshold level for background detection in SDS software was manually set to 0.2.

Data analysis
Quantile normalization was applied to the cycle threshold (CT) values. Samples with CT values of 32 and above were treated as undetected as recommended by the vendor. Fold change was calculated from raw CT values using the \( 2^{-\Delta CT} \) method [27]. The mean of the CT values of the 10 miRNAs with the lowest standard deviation was used as the endogenous control in the calculation of \( \Delta CT \). Statistical significance of differences in \( \Delta CT \) values between CRPS patients and controls was calculated by a 2-tailed independent samples t-test. The Benjamini-Hochberg false discovery rate correction [28] was applied to the p-values. Pairwise Spearman correlation was calculated between various clinical markers and miRNAs. Hierarchical clustering of miRNAs and samples was performed along with the generation of a heatmap of miRNA expression. The samples were clustered into three groups on the basis of their miRNA expression levels and the correlations of other variables against these three groups were calculated.

Determination of Cytokines/Chemokines and Their Soluble Receptors
The plasma was separated by centrifugation (3000 g for 15 minutes at 4°C), split into 250 μl aliquots and stored at -70°C. The Milliplex Map high sensitivity 10plex human cytokine kit (Millipore, Billerica, MA) was used to determine plasma levels of the following cytokines: interferon-gamma (IFNγ); the interleukins IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, and IL-10; and tumor necrosis factor alpha (TNFα). The Milliplex Map human soluble cytokine receptor panel (Millipore, Billerica, MA) was used to determine the following soluble receptors: soluble glycoprotein 130 (sgp130) (a subunit of the IL-6 receptor complex); the interleukin soluble receptors sIL-1R1, sIL-1R1II, sIL-2Rα, sIL-4R and sIL-6R; the TNFα soluble receptors sTNFRI and sTNFRII; and sRAGE, the soluble receptor for advanced glycation end products (AGEs). The plasma levels of the interleukin-1 receptor antagonist (IL1Ra) and the chemokine monocyte chemotactic protein-1 (MCP1) were determined with the Fluorokine MAP Multiplex Human Cytokine Panel A (R&D Systems, Minneapolis, MN). Assay results were determined on a Luminex-200 (Luminex, Austin, TX).

Results
The average age of controls and patients was 42 ± 12.7 and 45 ± 11.7 years, respectively. The female to male ratio was 14/6 for controls and 27/14 for patients with CRPS. Average body mass index (BMI) for controls and patients was 24.12 and 27.14 respectively indicating normal BMI for control and obesity in our CRPS patient population.

miRNA alterations in CRPS
Two-tailed t-tests were used to identify differential expression of miRNAs between patients and control samples. The fold changes and p-values of significantly altered miRNAs are shown in Table 1. A clustergram of the samples and miRNAs identifying sample subpopulations with respect to the significant differentially expressed miRNAs is shown in Figure 1 as a heat map of the log-transformed fold changes. Heat maps are commonly used for visualization of high-dimensional data in a two-dimensional image with colors representing the intensity values. It is typically used in gene expression analysis to represent the level of expression of many genes across a number of comparable samples. Clustering based on the fold change of significant miRNAs resulted in a clear separation of patient-only population from the rest of the subjects. A total of 60% of the patients (the right half of clustering) showed differential regulation for these miRNAs (mostly down regulation), whereas the rest of the patients were more heterogeneous.
and were clustered together with the control samples which showed considerable variability.

**Inflammatory markers**

Analysis of inflammatory markers including chemokines, cytokines and their soluble receptors in blood from the same individuals showed changes in several markers (Additional file 1). Though there were trends, t-tests (Benjamini-Hochberg adjustment of p values for multiple comparisons) showed that only VEGF, ILR1a and MCP1 levels were significantly elevated in CRPS patients (Figure 2). VEGF and ILR1a were significantly correlated with the reported pain levels of the patients. VEGF also had a significant correlation with BMI (Additional file 1).

**Analysis of subset of patients with CRPS**

Since 60% of the CRPS patients segregated based on miRNA profile (Figure 1 group 3), we analyzed this subgroup of patients further. Additional miRNAs that were identified to be significantly altered are shown in Table 2. For inflammatory and immune related markers, correlations of significance were observed for IL-6, IL-8, IL1Ra, MCP1 and VEGF when considering all CRPS patients versus control samples. Comparing subpopulation group3 against other samples identified additional correlations for IL-4, IL-5, and TNFalpha. However IL-6, IL-8

---

**Table 1 Fold changes and p values of significantly altered miRNAs**

| miRNA       | Fold change | p value  |
|-------------|-------------|----------|
| hsa-miR-939 | -4.59358    | 3.55E-06 |
| hsa-miR-25# | -3.92328    | 1.09E-06 |
| hsa-let-7c  | -2.53502    | 2.07E-05 |
| hsa-let-7a  | -2.45923    | 0.002308 |
| hsa-let-7b  | -2.40344    | 5.49E-05 |
| hsa-miR-320B| -2.0527     | 6.91E-06 |
| hsa-miR-126 | -2.02362    | 0.002469 |
| hsa-miR-629A| -1.71231    | 0.006653 |
| hsa-miR-664 | -1.54881    | 0.001487 |
| hsa-miR-320 | -1.44273    | 7.28E-05 |
| hsa-miR-1285| -1.41594    | 0.003077 |
| hsa-miR-625#| -1.33174    | 0.003542 |
| hsa-miR-S32-3p| -1.27226  | 0.001226 |
| hsa-miR-181a-2#| -1.25927  | 0.000229 |
| RNU48       | 1.348125    | 0.000391 |
| hsa-miR-720 | 1.476853    | 0.003243 |
| RNU44       | 1.854213    | 0.000904 |
| hsa-miR-1201| 2.14584     | 3.17E-05 |

Fold changes and p values of significantly altered miRNAs (minus sign indicates down-regulation; data sorted based on fold change). The statistical significance was calculated using 2-tailed t-tests on the miRNA expressions in CRPS patients versus control samples.
and MCP1 were not significant in group 3. Thus, stratifying the patient population on the basis of the miRNA profile resulted in changes, predominantly toward the identification of additional indicators that could be clinically relevant in CRPS.

Correlation analysis
We performed additional correlation analyses of all miRNAs detected in whole blood with other parameters including comorbidities. In addition to being in the list of 18 miRNAs identified to be differentially expressed in patients with CRPS, hsa-miR-532-3p was associated with CRPS type, pain level, IL1Ra, and VEGF (Table 3 and Additional file 1). CPRS Type-2 patients from our study had higher hsa-miR-532 and higher VEGF levels compared to CRPS Type-1 patients. We observed a strong correlation between miRNAs and comorbidities such as high blood pressure, cholesterol, thyroid disease, and use of narcotics and antiepileptic medications (Table 3 and Additional file 1). These miRNAs did not overlap with the miRNAs that were modulated in CRPS (Table 1). Though not our primary objective, these results identified miRNA alterations that may be specific to comorbid conditions observed in patients with CRPS. A Circos diagram [29] capturing the significant correlations among all parameters analyzed are shown in Figure 3.

Discussion
We observed differential expression of 18 miRNAs in whole blood from patients with CRPS compared to control samples. Thus multiple miRNAs were significantly different between patients and control subjects compared to three inflammatory and immune related markers. Clustering of 60% of patients with CRPS on the basis of the miRNA profile suggests that clinically relevant stratification of the patient population is possible on the basis of alterations in miRNA expression. miRNAs recognize their target mRNAs using the 2-8 nucleotide sequence at the 5' region of the miRNA called the seed sequence. Target prediction algorithms use different parameters to provide candidate target genes for miRNAs [30]. Our earlier success with TargetScan [23] led us to use TargetScan [31] to perform our initial analysis for miRNAs identified to be differentially expressed in CRPS (data not shown). Bioinformatic prediction of the significantly altered miRNAs showed that these miRNAs can potentially modulate miRNAs of a number of genes relevant in CRPS including inflammatory mediators, ion channels, and G protein-coupled receptors. For example, a bioinformatics-based prediction indicates that hsa-miR-939 can target vascular endothelial growth factor A (VEGF A), inducible nitric oxide synthase 2A, and the alpha subunit of voltage-gated sodium channel type IV and that hsa-miR-25 can target endothelin receptor type B. Since one of the predicted gene targets for hsa-miR-939 is VEGF A, the upregulation of VEGF in the serum of CRPS patients strengthens the prediction. Additional studies including reporter gene assays to validate these predictions and functional consequences of miRNA alterations can

---

**Table 2 Significantly altered miRNAs for samples**

| Variable       | p value | Variable       | p value |
|----------------|---------|----------------|---------|
| hsa-miR-25#    | 9.29E-09| hsa-miR-20a#   | 0.00454 |
| hsa-let-7c     | 4.33E-08| hsa-miR-16-1#  | 0.005137|
| hsa-let-7b     | 7.35E-08| hsa-miR-106b   | 0.00535 |
| hsa-miR-320    | 6.06E-07| hsa-miR-532-3p | 0.00535 |
| hsa-miR-181a-2#| 6.64E-05| hsa-miR-142-5p | 0.005419|
| hsa-miR-190b   | 0.0006  | hsa-miR-342-5p | 0.005419|
| hsa-miR-221    | 0.000721| hsa-miR-155    | 0.00595 |
| hsa-miR-629    | 0.002053| hsa-miR-130b   | 0.007069|
| hsa-miR-93     | 0.002053| hsa-miR-185    | 0.007069|
| hsa-miR-590-5p | 0.002053| hsa-miR-181c   | 0.007069|
| hsa-miR-29b-2# | 0.00306  | hsa-miR-20b    | 0.007154|
| hsa-miR-181a   | 0.003087| hsa-let-7a     | 0.009386|
| hsa-miR-144#   | 0.003087| hsa-miR-422a   | 0.009471|
| hsa-miR-196b   | 0.003908| hsa-miR-340    | 0.009501|
| hsa-miR-132    | 0.004131| hsa-miR-324-3p | 0.009501|
| hsa-miR-652    | 0.004131| hsa-miR-598    | 0.009975|
| hsa-let-7g     | 0.004305| hsa-let-7d     | 0.009975|

Significantly altered miRNAs for samples that clustered in Group 3, based on the miRNA profiling. The statistical significance was calculated using 2-tailed t-tests on the miRNA expression levels in patients that were in Group 3 versus other CRPS patients and control samples.
provide mechanistic insight into the mode of action of miRNAs in CRPS.

The miRNAs shown in Figure 1 from the CRPS study were compared with miRNAs altered in some of the rodent models for pain investigated. While there was no overlap in the miRNAs identified from studies that focused on a limited number of miRNAs, [19-22,25] profiling from dorsal root ganglion (DRG) from the rat spinal nerve ligation (SNL) model [23] showed that the expression of four miRNAs hsa-miR-126, hsa-let-7a, hsa-let-7b and hsa-let-7c (multiple copies of let-7 family of miRNAs are present in the genome; isoforms are distinguished by a letter placed after let-7 to indicate a slightly different sequence) was significantly altered in

| Variable 1                  | Variable 2       | Correlation | p value  |
|-----------------------------|------------------|-------------|----------|
| CRPS type                   | hsa-miR-332-3p   | 0.4448      | 0.00782  |
| CRPS duration               | hsa-miR-151-5p   | 0.45992     | 0.00574  |
| Pain level                  | hsa-miR-296-5p   | 0.50218     | 0.00222  |
|                            | hsa-miR-361-3p   | 0.48489     | 0.00333  |
|                            | hsa-miR-352-3p   | 0.46868     | 0.00478  |
|                            | hsa-miR-30d      | 0.43451     | 0.00957  |
| Immomov (inability to initiate and maintain fine movements) | hsa-miR-218     | 0.46241     | 0.00546  |
| High blood pressure         | hsa-miR-92a      | -0.5583     | 0.0005   |
|                            | hsa-miR-484      | -0.4422     | 0.00822  |
| High cholesterol            | hsa-miR-219-1-3p | -0.4847     | 0.00334  |
|                            | hsa-miR-204      | 0.46688     | 0.00497  |
| Headache                    | hsa-miR-616      | 0.57271     | 0.00039  |
|                            | hsa-miR-548d-3p  | 0.48307     | 0.00391  |
|                            | hsa-miR-27a      | 0.45319     | 0.00733  |
|                            | hsa-miR-345      | 0.45319     | 0.00733  |
|                            | hsa-miR-324-5p   | 0.45319     | 0.00733  |
|                            | hsa-miR-192      | 0.45319     | 0.00733  |
|                            | hsa-miR-28-5p    | 0.44821     | 0.00808  |
|                            | hsa-miR-502-5p   | 0.44821     | 0.00808  |
| Thyroid disease             | hsa-miR-616      | 0.57271     | 0.00039  |
|                            | hsa-miR-548d-3p  | 0.48307     | 0.00391  |
|                            | hsa-miR-27a      | 0.45319     | 0.00733  |
|                            | hsa-miR-345      | 0.45319     | 0.00733  |
|                            | hsa-miR-324-5p   | 0.45319     | 0.00733  |
|                            | hsa-miR-192      | 0.45319     | 0.00733  |
|                            | hsa-miR-28-5p    | 0.44821     | 0.00808  |
|                            | hsa-miR-502-5p   | 0.44821     | 0.00808  |
| Hyposthesia                 | hsa-miR-616      | 0.57271     | 0.00039  |
|                            | hsa-miR-150      | 0.49815     | 0.00245  |
| Narcotics                   | hsa-miR-548d-3p  | 0.48307     | 0.00391  |
|                            | hsa-miR-27a      | 0.45319     | 0.00733  |
|                            | hsa-miR-345      | 0.45319     | 0.00733  |
|                            | hsa-miR-324-5p   | 0.45319     | 0.00733  |
|                            | hsa-miR-192      | 0.45319     | 0.00733  |
|                            | hsa-miR-28-5p    | 0.44821     | 0.00808  |
|                            | hsa-miR-502-5p   | 0.44821     | 0.00808  |
| Epileptic Drugs             | hsa-miR-616      | 0.57271     | 0.00039  |
|                            | hsa-miR-548d-3p  | 0.48307     | 0.00391  |
|                            | hsa-miR-27a      | 0.45319     | 0.00733  |
|                            | hsa-miR-345      | 0.45319     | 0.00733  |
|                            | hsa-miR-324-5p   | 0.45319     | 0.00733  |
|                            | hsa-miR-192      | 0.45319     | 0.00733  |
|                            | hsa-miR-28-5p    | 0.44821     | 0.00808  |
|                            | hsa-miR-502-5p   | 0.44821     | 0.00808  |
| BMI                         | hsa-miR-145#     | 0.43337     | 0.00978  |
|                            | hsa-miR-296-5p   | 0.41312     | 0.00239  |
|                            | hsa-miR-1290     | -0.3842     | 0.00507  |
|                            | hsa-miR-423-5p   | 0.38146     | 0.00544  |
|                            | hsa-miR-25#      | 0.3774      | 0.00599  |
|                            | hsa-miR-1270     | 0.35921     | 0.00918  |

All additional correlations observed including inflammatory markers, groups 1, 2 and 3 based on miRNA profiling, clinical parameters etc. are shown in Supplementary table 1

Table 3 Correlation studies in CRPS patients for miRNAs, comorbidities and medication

Orlova et al. Journal of Translational Medicine 2011, 9:195
http://www.translational-medicine.com/content/9/1/195
both CRPS blood and rat DRG after SNL. Profiling of 369 miRNAs was performed in rat DRG 4 weeks post SNL [23], whereas the current study profiled 758 miRNAs. Thus, not all miRNAs identified in the present CRPS study have been profiled in rat DRG. This finding is an indication of the potential translational value that can be achieved from miRNA profiling.

Expression of small nucleolar RNAs (snoRNAs) RNU44 and RNU48 was found to be altered in CRPS patients. RNU44 and RNU48 have been widely used for...
miRNA data normalization, but a recent study reported that normalizing miRNA expression data to these recommended snoRNAs introduced bias in associations between miRNA and pathology or outcome [32]. Their function is not well understood, but recent reports suggest that the noncoding growth arrest-specific transcript 5 gene (GASS), which encodes multiple snoRNAs, is significantly downregulated in breast cancer [33]. GASS is necessary and sufficient for the arrest of T-cell growth and for the inhibitory effects of rapamycin and its analogues. It has been suggested that these effects may be mediated through the snoRNAs. These observations have important clinical implications because these compounds are used in immunosuppression and in cancer therapy [34].

Though the pathophysiology of CRPS is not completely understood, it is known that neurogenic inflammation plays a significant role [35]. Studies suggest that trauma-induced release of inflammatory cytokines facilitates neurogenic inflammation [35,36]. Mast cells, neutrophils and macrophages are recruited to the injured area and because of the compromised blood-nerve barrier they invade the nerve [37]. These cells release proinflammatory cytokines that have been implicated in the generation of neuropathic pain either by direct sensitization of nociceptors or indirectly by stimulating the release of agents that act on neurons and glia [38,39]. Thus both neuroinflammation and neuroimmune activation act in concert in persistent pain states [40]. The balance between pro- and anti-inflammatory cytokines may ultimately determine the chronic pain state [41]. An increase in the level of proinflammatory cytokine IL-2 and a decrease in the level of anti-inflammatory cytokines IL-4 and IL-10 were reported in CRPS [42,43]. However, systemic inflammatory cytokine responses have been inconsistent between the different study populations and settings. Trends toward an increase in proinflammatory cytokines (IL-6, IL-8, TNF alpha) and a decrease of the anti-inflammatory cytokine IL-10 in CRPS subjects compared with the controls have been observed but none of the changes reached statistical significance [44]. It has not yet been established clinically that measurement of plasma cytokines is helpful in the diagnosis or follow-up of CRPS patients. However, in a recent study using a large patient population, clustering patterns showed that plasma cytokine levels should not be evaluated in isolation and that their effect may differ depending on the plasma level of their soluble receptors and receptor antagonists [45]. When all CRPS patients were analyzed only VEGF, MCP1 (CCL2) and IL1Ra were significantly regulated whereas grouping patients based on miRNA profiling (Group 3) resulted in additional markers that were significantly altered including TNFalpha, IL-4 and IL-5. miRNAs associated with comorbidities and medications (Table 3) were different from those associated with CRPS.

We observed hsa-mir-150 to be correlated with headache and several other miRNA correlations with comorbidities such as high blood pressure, thyroid disorder, use of medications including narcotics and antiepileptic drugs. These results indicate the broader utility of performing miRNA profiling and could provide additional molecular insights into disease biology occurring as comorbidities or use of specific medications.

Our studies indicate that miRNA profiling can serve as a novel approach for patient stratification. Stratification based on the miRNA profile resulted in identification of additional markers that were not significant when all CRPS patients were analyzed as a single group. Stratification of patients can be clinically relevant in CRPS and additional patterns could emerge with increase in sample size. The potential for identifying several miRNAs as signatures rather than relying on one specific biomarker will increase the chances of successful treatment in the heterogeneous CRPS patient population. Identifying informative benchmarks will be an exceptionally valuable tool for assisting physicians in choosing treatment options and for stratifying patients in clinical trials. By performing similar miRNA profiling in animal models to cross validate the human data, we can gain further insight into mechanistic aspects of CRPS. miRNAs or the genes they modulate can be direct targets for future therapeutic interventions. Bridging preclinical and clinical results could provide new insights into the molecular mechanisms underlying chronic pain.

The functional relevance of the presence of stable miRNAs in blood is an area of active investigation. A recent study demonstrated a novel mechanism of intercellular communication involving the transport and delivery of miRNAs [46]. Intercellular communication was thought to be limited to cell-to-cell adhesion conduits (gap junctions) or secreted signals such as hormones and neurotransmitters; however, it has been shown that miRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins resulting in modulation of target miRNAs [46]. Delivery of miRNAs to recipient cells with functional gene regulatory consequences via blood opens up novel avenues for target intervention. Identification and functional validation of miRNAs modulated by miRNAs altered in the blood of patients with CRPS can thus demonstrate the potential for miRNA to regulate the expression of pain-relevant genes. These studies can lead to a greater understanding of the molecular mechanisms involved in chronic pain and potentially determine if any of the miRNAs or the genes they modulate can be direct targets for future therapeutic interventions.
Conclusions

The ability to cluster 60% of the patients with CRPS suggests that miRNA profiling can serve as a novel, clinically relevant approach for patient stratification. Grouping patients based on miRNA profiling resulted in the identification of additional markers that were not significant when the whole CRPS population was considered. This could be due to the etiology as well as the multitude of pathologies and symptoms associated with CRPS. Correlational studies linking miRNA changes with inflammatory markers and clinical parameters provided a broad overview of the interplay of multiple factors critical in CRPS. Additional studies validating the role of the miRNAs in gene regulation can help to obtain insights into molecular mechanisms underlying CRPS.

Additional material

Additional file 1: Correlation studies for miRNAs, comorbidities and medication. Significant correlations observed including 1) miRNA and clinical parameters, 2) miRNA and inflammatory markers, 3) miRNA and groups, 4) inflammatory and immune related markers, and 5) clinical parameters are shown in sheets 1, 2, 3, 4 and 5 respectively. Groups in sheet 3 includes CRPS vs. healthy as well as CRPS subpopulation 1, CRPS subpopulation 2 and CRPS subpopulation 3 representing group 1, 2 and 3 based on differential expression of miRNAs.

List of abbreviations

3′/5′UTR, 3′ untranslated region of messenger RNAs; AGES: advanced glycation end products; BMI: body mass index; CRPS: complex regional pain syndrome; CT: cycle threshold; DRG: dorsal root ganglion; hsa-mir: Homo sapiens-microRNA; IL: interleukin; IL1Ra: interleukin1 receptor antagonist; MCP1: monocyte chemotactic protein-1; NRS: numerical rating scale; s: soluble; sTNF: soluble tumor necrosis factor; sTNFR: soluble tumor necrosis factor receptor; TLDA: Taqman low density array; TNFα: tumor necrosis factor alpha; VEGF: vascular endothelial growth factor.

Acknowledgements

This study was supported by funds from Rita Allen Foundation grant in conjunction with American Pain Society to S.K.A. Funding agency had no role in design, in the collection, analysis, and interpretation of data, in the writing of the manuscript, and in the decision to submit the manuscript for publication.

Author details

1Pharmacology & Physiology, Drexel University College of Medicine, Philadelphia, PA 19102, USA. 2Neurology, Drexel University College of Medicine, Philadelphia, PA 19102, USA. 3School of Biomedical Engineering, Science, and Health Systems, Drexel University, Philadelphia, PA 19104, USA.

Authors’ contributions

IO carried out the miRNA profiling and analyzed the data; GA participated in study design, study supervision and coordination, data acquisition of inflammatory markers, analysis and interpretation of data, and drafted the manuscript; RQ performed bioinformatics and statistical analysis, revised the manuscript; JK performed statistical analysis, interpretation of data and revised the manuscript; JB participated in study design, data interpretation and revising the manuscript; RS performed all the clinical exams, study supervision and coordination in the clinic, revised the manuscript; SA conceived the study concept, performed study supervision, coordination, data analysis, interpretation of data and wrote the manuscript. All authors read and approved the final manuscript.

Competing interests

The authors declare that they have no competing interests. A provisional patent has been filed relating to the content of the manuscript.

Received: 7 September 2011 Accepted: 10 November 2011

Published: 10 November 2011

References

1. Schwartzman RJ, Alexander GM, Grothuesen J: Pathophysiology of complex regional pain syndrome. Expert Rev Neurother 2006, 6:669-681.
2. Schwartzman RJ, Erwin KL, Alexander GM: The natural history of complex regional pain syndrome. Clin J Pain 2009, 25:273-280.
3. Costigan M, Scholz J, Woolf CJ: Neuropathic pain: a maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009, 32:1-32.
4. Mahofner C, Seiffert F, Markovic K: Complex regional pain syndromes: new pathophysiological concepts and therapies. Eur J Neurol 2010, 17:649-660.
5. Harden RN, Bruehl S, Stanton-Hicks M, Wilson PR: Proposed new diagnostic criteria for complex regional pain syndrome. Pain Med 2007, 8:326-331.
6. Barat DP: MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
7. Cerman S, Saugstad J: MicroRNAs: Meta-controlers of gene expression in synaptic activity emerge as genetic and diagnostic markers of human disease. Pharmacol Ther 2011, 130:26-37.
8. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 2008, 18:1097-1106.
9. Mitchell PS, Parkin RK, Koh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O’Brien KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 2008, 105:10513-10518.
10. Cortez MA, Cailin GA: MicroRNA identification in plasma and serum: a new tool to diagnose and monitor diseases. Expert Opin Biol Ther 2009, 9:703-711.
11. Park NJ, Zhou H, Elashoff D, Henson BS, Elashoff D, Henson BS, Kastratovic DA, Abemayor E, Wong DT: Salivary microRNA: discovery, characterization, and clinical utility for oral cancer detection. Clin Cancer Res 2009, 15:5473-5477.
12. Glad S, Meir E, Yogeiv Y, Benjamin S, Lebanozhi D, Yeshulami N, Benjamin H, Kushner M, Chalikian H, Melamed N, et al: Serum microRNAs are promising novel biomarkers. PLoS One 2008, 3:e3148.
13. Hanke M, Hoefig K, Meier H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G: A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol 2009.
14. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, Lee MJ, Galas DJ, Wang K. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
15. Etheridge A, Lee I, Hood L, Galas D, Wang K. Extracellular microRNA: A new source of biomarkers. Mutat Res 2011.
16. Scholer N, Langer C, Doheiner H, Buske C, Kuchenbauer F. Serum microRNAs as a novel class of biomarkers: a comprehensive review of the literature. Exp Hematol 2010, 38:1126-1130.
17. Wehling M: Translational medicine: can it really facilitate the transition of research “from bench to bedside”? Eur J Clin Pharmacol 2006, 62:91-95.
18. Frank R, Hargreaves R: Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003, 2:566-580.
19. Bai G, Arbab ZA, Wei D, Dessem D, Dessem D. Downregulation of selective microRNAs in trigeminal ganglion neurons following inflammatory muscle pain. Mol Pain 2007, 3:15.
20. Kusuda R, Cadet R, Ravanielli M, Sousa TA, Zanon S, de Lucca F, Lucas G. Differential expression of microRNAs in mouse pain models. Mol Pain 2011, 7:17.
21. Poh KW, Yeo JF, Ong WK: MicroRNA changes in the mouse prefrontal cortex after inflammatory pain. Eur J Pain 2011, 15:801-812.
22. Aldrich BT, Frakes EP, Kasuya J, Hammond DL, Kitamoto T. Changes in expression of sensory organ-specific microRNAs in rat dorsal root...
ganglia in association with mechanical hypersensitivity induced by spinal nerve ligation. Neurosci Lett 2009, 467:711-723.
23. von Schack D, Agostino MJ, Murray BS, Li Y, Reddy PS, Chen J, Choe SE, Striessnig BW, Li C, Baten B, et al.: Dynamic changes in the microRNA expression profile reveal multiple regulatory mechanisms in the spinal nerve ligation model of neuropathic pain. PLoS One 2011, 6:e17670.
24. Zhao J, Lee MC, Momin A, Cendan CM, Shepherd ST, Baker MD, Asante C, Bee L, Ethy A, Perkins JR, et al.: Small RNAs control sodium channel expression, nociceptor excitability, and pain thresholds. J Neurosci 2010, 30:10860-10871.
25. Favereaux A, Thoumine Q, Bouali-Benazzouz R, Roques V, Papou MA, Salam SA, Drutel G, Leger C, Calas A, Nagy F, Landry M: Bidirectional integrative regulation of Cav1.2 calcium channel by microRNA miR-103: role in pain. EMBO J 2011, 30:3830-3841.
26. Li X, Gibson G, Kim JS, Kuo J, Xu S, van Wijnen AJ, Im HJ: MicroRNA-146a is linked to pain-related pathophysiology of osteoarthritis. Gene 2011, 480:34-41.
27. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the comparative CT method. Nat Protoc 2008, 3:1101-1108.
28. Hochberg YBaY: Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society 1995, 57:289-300.
29. Krzywinski M, Schein J, Brol I, Connors J, Gascoyne R, Horsman D, Jones SJ, Maara MA: CIRCos: an information aesthetic for comparative genomics. Genome Res 2009, 19:1639-1645.
30. Sethupathy P, Megraw M, Hatzigeorgiou AG: A guide through present computational approaches for the identification of mammalian microRNA targets. Nat Methods 2006, 3:881-886.
31. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
32. Gao HE, Buffa FM, Camps C, Ramachandran A, Leek T, Taylor M, Patil M, Sheldon H, Betts G, Homer J, et al.: The small-nuclear RNAs commonly used for microRNA normalisation correlate with tumour pathology and prognosis. Br J Cancer 2011, 104:1168-1177.
33. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT: GASS, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009, 28:195-208.
34. Williams GT, Mourtada-Maarabouni M, Farzaneh F: A critical role for non-coding RNA GASS in growth arrest and rapamycin inhibition in human T-lymphocytes. Biochem Soc Trans 2011, 39:483-486.
35. Schinkel C, Gaertner A, Zaspel J, Zedler S, Faist E, Schuermann M: Inflammatory mediators are altered in the acute phase of posttraumatic complex regional pain syndrome. Clin J Pain 2006, 22:235-239.
36. Huygen FJ, De Brujin AG, De Bruin MT, Groeneveld JG, Klein J, Zijlstra FJ: Evidence for local inflammation in complex regional pain syndrome type I. Mediators Inflamm 2002, 11:4751.
37. Marchand F, Perretti M, McMahon SB: Role of the immune system in chronic pain. Nat Rev Neurosci 2005, 6:521-532.
38. Abbadi C, Chemokines, chemokine receptors and pain. Trends Immunol 2005, 26:529-534.
39. Watkins LR, Maier SF: Glia: a novel drug discovery target for clinical pain. Nat Rev Drug Discov 2003, 2:973-985.
40. Delio JA, Yezierski RP: The role of neuroinflammation and neuroimmune activation in persistent pain. Pain 2001, 90:1-6.
41. Austin PJ, Moalem-Taylor G: The neuro-immune balance in neuropathic pain: involvement of inflammatory immune cells, immune-like gial cells and cytokines. J Neuroimmunol 2010, 229:26-50.
42. Uceteley N, Ebelke T, Rolke L, Ridke F, Sommer C: Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007, 132:195-205.
43. Uceteley N, Rogausch JP, Toya KV, Sommer C: Differential expression of cytokines in painful and painless neuropathies. Neurology 2007, 69:42-49.
44. Ritz BW, Alexander GW, Nogusa S, Perreault MJ, Peterlin BL, Grothusen JR, Schwartzman RJ: Elevated blood levels of inflammatory monocytes (CD14+ CD16+) in patients with complex regional pain syndrome. Clin Exp Immunol 2011, 164:106-117.
45. Alexander GM, Peterlin LB, Perreault MJ, Grothusen JR, Schwartzman RJ: Changes in plasma cytokines and their soluble receptors in complex regional pain syndrome. J Pain 2011.